Products

Our pipeline: Delivering first-in-class immunotherapies of activation and regulation

 

Three areas of expertise are being developed within our immunology research platform

  • T-cell-based vaccination
  • Immuno-Oncology
  • Auto-Immune Diseases & Inflammation
Product
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Neo-epitopes
NSCLC post-ICI failure
Final results of Atalante trial presented at ESMO 2021
Neo-epitopes
Advanced pancreatic cancer
Neo-epitopes
Ovarian cancer in combination with Keytruda®
Neo-epitopes
NSCLC in combination with Opdivo®
Epitopes
Second-generation COVID-19 vaccine
CD47-SIRPa antagonist
Solid tumors
Myeloid checkpoint
Various cancers
Anti-PD1 + Innovative targets
Various cancers
IL-7R Antagonist
Ulcerative colitis (OSE), Sjögren's syndrome (Servier)
CD28 Antagonist
Auto-immune diseases (OSE), Transplantation (Veloxis)
Anti-ChemR23 agonist
Resolution of inflammation

Significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€72 M already received since 2016)

The 3 areas of expertise

Three areas of expertise are being developed within our immunology research platform:

  • T-cell based vaccination
  • Immuno-Oncology (focus on myeloid targets)
  • Auto-Immunity & Inflammation

To receive OSE Immunotherapeutics’ latest news